Forbes Article “Going Beyond Target Or Mechanism Of Disease: Disruptive Innovation In Drug Delivery Systems”

Privo is excited to share the recent Forbes article titled, “Going Beyond Target Or Mechanism Of Disease: Disruptive Innovation In Drug Delivery Systems” written by one of our manuscript authors, Alex Zhavoronkov, PhD that highlights our nanoengineered PRV Platform.    Click the below to access the fill Forbes article.

Going Beyond Target Or Mechanism Of Disease: Disruptive Innovation In Drug Delivery Systems (forbes.com)

Link to Nature Communications publication on the PRV Platform is also provided below.

A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in animal models and patients with oral cancer | Nature Communications

Media Contact: communicationteam@app-privo-wp.azurewebsites.net 

September 8, 2022

Share this post

Author

Related Posts

14Nov

Privo Technologies earns first ever runner-up placement at the Salisbury Award competition in Bethesda, Maryland.

The Salisbury Award Competition is a set of competitions participated in by investigators at major cancer research institutions and/or scientists at... read more

02Dec

MIT Selects Privo Technologies To Showcase the Company’s Groundbreaking Cancer Therapy in Japan and Korea.

Privo Technologies (Privo), a Massachusetts-based company with roots in the Langer lab at MIT, has been selected to introduce its... read more

02Dec

Privo Technologies, Inc. Receives IRB Approval for PRV211- Intraoperative Chemotherapy Treatment for Solid Tumors

Privo Technologies, Inc. is pleased to announce that it has received IRB approval for its CLN-004 study from WCG... read more

10Jan

Honored at the White House Privo Technologies receives the 2016 National Tibbetts Award

Privo Technologies is pleased to announce that the company has won the 2016 National Tibbetts award for outstanding contributions to... read more

07Sep

FDA Grants $2 million award to Privo Technologies to expedite its clinical trial

Privo Technologies has been awarded ~$2 million in funding from the FDA through its Office of Orphan Product Development (OOPD)... read more

01Apr

National Cancer Institute awards

Privo a $2.5M grant to optimize it lead product and prepare for its IND. read more

13Sep

Privo receives Commercialization Award from the National Cancer Institute

Privo Technologies is proud to serve as both an exhibitor and selected speaker at the RESI conference in Boston and... read more

01Jan

Our Oral Cancer treatment receives MIT’s Innovation Award two years in a row.

The project was awarded over $300,000 in funding from MIT’s Deshpande Innovation Center in 2012 and 2013 to support the... read more

06Jun

BIO International Convention

Privo Technologies attends BIO International Convention as an invited guest of the National Institute of Dental and Craniofacial Research Institute... read more

10Dec

Privo Technologies receives 2015 TechConnect Innovation Award

Privo Technologies received the “2015 National Innovation Award” from the TechConnect World Innovation Conference. Privo’s ChemoThin Wafer project was rated... read more

Contact Us
close slider

Contact Us